BOSTON, Massachusetts — November 5, 2025 — Leads & Copy — Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its third quarter 2025 financial results and provided a business update. The company expects to report overall survival (OS) and progression-free survival (PFS) data in late Q1 2026 from its Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), due to a continuing trend of decreased mortality.
A new response has been observed in a third indication in the fifth and final dosing cohort of the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody). Topline data are expected to be presented at a medical meeting in H1 2026, as no dose-limiting toxicities have been observed at any dose level.
Cohort expansions in patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), are expected to begin in Q4 2025, based on previously reported responses in the CTX-8371 Phase 1 study.
CTX-10726 (PD-1 x VEGF-A bispecific antibody) IND filing is planned for Q4 2025 with initial Phase 1 clinical data expected in H2 2026.
Compass Therapeutics had $220 million in cash and marketable securities as of September 30, 2025, which is expected to provide cash runway into 2028.
Pipeline highlights include Tovecimig (DLL4 and VEGF-A bispecific antibody), CTX-8371 (PD-1 x PD-L1 bispecific antibody), CTX-10726 (PD-1 x VEGF-A bispecific antibody) and CTX-471 (CD137 agonist antibody).
Net loss for the quarter ended September 30, 2025, was $14.3 million or $0.08 per share of common stock, compared to $10.5 million or $0.08 per share of common stock for the same period in 2024. As of September 30, 2025, cash and marketable securities were $220 million as compared to $127 million as of December 31, 2024, providing the Company with an anticipated cash runway through 2028.
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
Source: Compass Therapeutics
